883 related articles for article (PubMed ID: 19118069)
1. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed in first-line treatment of non-small cell lung cancer.
Esteban E; Casillas M; Cassinello A
Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
Scagliotti GV; Kortsik C; Dark GG; Price A; Manegold C; Rosell R; O'Brien M; Peterson PM; Castellano D; Selvaggi G; Novello S; Blatter J; Kayitalire L; Crino L; Paz-Ares L
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):690-6. PubMed ID: 15701857
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
14. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
[TBL] [Abstract][Full Text] [Related]
17. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK
J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer.
Li BS; Gong HY; Huang W; Yi Y; Yu JM; Wang ZT; Zhang ZC; Sun HF; Li HS; Wang LY
Am J Clin Oncol; 2012 Apr; 35(2):115-9. PubMed ID: 21555933
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]